Primary Prevention Management of Elevated Lipoprotein(a)

Anandita Agarwala; Christie Ballantyne; Neil J Stone

doi:10.1001/jamacardio.2022.4063

Primary Prevention Management of Elevated Lipoprotein(a)

JAMA Cardiol. 2023 Jan 1;8(1):96-97. doi: 10.1001/jamacardio.2022.4063.

Authors

Anandita Agarwala¹, Christie Ballantyne², Neil J Stone^{3

4}

Affiliations

¹ Center for Cardiovascular Disease Prevention, Cardiovascular Division, Baylor Scott & White The Heart Hospital-Plano, Plano, Texas.
² Sections of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
³ Feinberg School of Medicine, Department of Medicine (Cardiology), Northwestern University, Chicago, Illinois.
⁴ Feinberg School of Medicine, Department of Preventive Medicine, Northwestern University, Chicago, Illinois.

PMID: 36383356
DOI: 10.1001/jamacardio.2022.4063

No abstract available

Plain language summary

A male individual in his 40s with a strong family history of atherosclerotic cardiovascular disease including premature cardiovascular events in multiple family members presents to your clinic to establish care for cardiovascular risk stratification. What would you do next?

MeSH terms

Atherosclerosis*
Humans
Hyperlipidemias*
Lipoprotein(a)
Primary Prevention

Substances

Lipoprotein(a)